Articles tagged with Cervical Cancer
The American College of Physicians recommends against routine pelvic exams for asymptomatic, average-risk women due to low diagnostic accuracy and potential harms. The guideline suggests that pelvic exams are appropriate only for women with symptoms or certain risk factors.
Researchers recommend increasing cervical cancer screenings to reduce rates, regardless of test choice. Co-testing with Pap and HPV detects most pre-cancer, but improvement is small compared to repeat Pap testing every three years.
Increasing cervical cancer screening rates can help prevent invasive cancer. Experts recommend focusing on population coverage rather than choosing a specific test. Meanwhile, the release of Medicare data provides insights into healthcare spending and quality, but lacks meaningful context for evaluation.
Researchers have made significant strides in developing innovative immunotherapies that activate the body's immune response to fight cancer. The new treatments show high activity against advanced melanoma and demonstrate substantial decrease in melanoma recurrence risk.
A new study reveals that US cervical cancer rates are higher than previously believed, particularly among women over 65 and African-American women. The study found an age-standardized rate of 18.6 cases of cervical cancer per 100,000 women, with incidence increasing steadily with age.
A new study suggests that US cervical cancer incidence rates may be underestimated due to the inclusion of women who have undergone a hysterectomy in calculations. Rates were found to increase with age, particularly among older women and black women.
Recent guidelines on cervical cancer screening have left clinicians and patients with a question about the best approach. Experts recommend considering individual patient values and preferences when choosing between Pap testing alone and cotesting with HPV testing.
Researchers found that women treated with radiation for cervical cancer were at higher risk of developing colon and rectal cancers, with some cases appearing up to 35 years after initial diagnosis. The study suggests new screening guidelines for young survivors, starting eight years after diagnosis.
A study found a significant reduction in HPV types 16 and 18 infections among young women in England after the introduction of the HPV vaccination program. The prevalence dropped from 1 in 5 to 1 in 15 among those aged 16-18, with the lowest rates among vaccinated individuals.
A recent study in Human Vaccines & Immunotherapeutics found that two doses of the HPV-16/18 AS04-adjuvanted vaccine Cervarix are non-inferior to three doses, providing similar protection against cervical cancer. The two-dose schedule showed a clinically acceptable safety profile and induced strong antibody responses.
A preclinical study suggests that AHCC supplement can eliminate HPV infections and may have a role in preventing HPV-related cancers. The study found durable responses after treatment with AHCC for up to 90 days, with no side effects observed.
Research reveals young women most at risk of cervical cancer are least likely to be offered and complete the HPV jab. The survey found that these women need targeted efforts to improve vaccination uptake, which was below 80% required for significant impact on cervical cancer rates.
A new clinical study found that erlotinib significantly improved treatment outcomes for women with locally advanced cervical cancer. After two years, 91.7% of patients were alive and experienced no disease progression.
A multi-site research project led by Dr. Bradley J. Monk found that women with advanced cervical cancer live an average of 17 months longer when combined with bevacizumab and chemotherapy compared to chemotherapy alone. The study reveals a significant improvement in treatment outcomes for patients with metastatic cervical cancer.
A commonly-used HIV drug has been shown to kill-off the human papilloma virus (HPV) that leads to cervical cancer. The study found a high proportion of women diagnosed with HPV positive high-grade disease returned to normal following a short course of the new treatment.
A Swedish register study found that receiving three doses of HPV vaccine significantly reduces the incidence of genital warts compared to two doses. The study, published in JAMA, suggests that a three-dose regimen may be more effective in preventing genital warts than previously thought.
A study found that receiving two doses of the HPV vaccine significantly reduces the risk of genital warts and other STDs. The vaccine's efficacy was seen to decrease after three doses, but it still offers substantial protection against these diseases.
A new study by University of Kentucky researchers identified four key barriers to cancer screening in Appalachian women, including embarrassment about Pap tests and lack of health insurance. These barriers contribute to higher mortality rates for invasive cervical cancer in the region, with a 67% increase compared to national averages.
A Moffitt Cancer Center study found that consistent HPV vaccine recommendations from family doctors are lacking, contributing to low vaccination rates. The research team recommends more HPV vaccine recommendations by family physicians to increase uptake.
A pilot study of 100,242 Mexican women found that large-scale HPV self-testing is as effective as conventional cytology screening in detecting cancer. However, the increased demand for follow-up care led to a decline in clinical quality. The researchers advocate for strengthened follow-up services to support home testing.
Researchers are developing a new diagnostic technique using infrared light to identify chemical changes in cells that lead to cancer development. The technology has the potential to detect alterations in both cancer and surrounding stromal cells, helping diagnosis and therapy development.
A phase II clinical trial of Avastin (Bevacizumab) with cisplatin and pelvic radiation for locally advanced cervical cancer showed promising results. The study found improved overall survival rates of 89.8% at 2 years and 80.2% at 3 years compared to historical controls.
Women aged 50-64 who are screened regularly have a lower risk of cervical cancer into their eighties. Screening up to age 65 greatly reduces cervical cancer risk, but protection weakens with time.
A study published in PLOS Medicine found that cervical screening up to age 69 reduces cervical cancer risk, with benefits for women with normal screening results. Regular screening can save lives and reduce cancer rates beyond age 50.
A study found that women previously treated for CIN3 have an increased risk of developing and dying from cervical or vaginal cancer compared to the general female population. The risk accelerates above age 60 and is more pronounced in those who received treatment later in life.
The study reveals that E6AP is composed of three distinct protein molecules, controlling nerve cell function and viral replication. This breakthrough provides potential drug targets for autism and cervical cancer treatment.
A new plasma thermogram test has been developed by researchers at the University of Louisville, indicating the presence or absence of cervical cancer. The test measures unique protein signatures in blood plasma, providing a non-invasive alternative to traditional Pap smear screening.
A comprehensive genomic analysis of cervical cancer identified recurrent genetic mutations, including one targeted by existing treatments for other cancers. The study also shed light on the role of human papillomavirus (HPV) in cervical cancer development.
A recent survey found that most people with relevance to HPV vaccination were unaware of its efficacy in preventing cervical cancer. The study suggests encouraging healthcare providers to discuss the vaccine's effectiveness with patients and parents of eligible adolescents to reduce cervical cancer incidence and mortality.
A recent study found that nearly two-thirds of women who have had hysterectomies and half of women over 65 with no cervical cancer history received unnecessary Pap tests. The U.S. Preventive Services Task Force has recommended against these groups for the test since 2003.
The study aims to investigate the effectiveness of treating precancerous lesions in reducing the incidence of anal cancer in HIV-infected men and women. The project will enroll 5,058 participants and follow them for up to five years to determine the incidence of cancer.
A study by Michigan Medicine found that female family physicians are more likely to order the HPV test for low-risk women aged 30-65 compared to their male counterparts. The likelihood of ordering the test also varies among clinics and physician training levels.
A lack of state-level coordination and organization is hindering efforts to address cervical cancer, according to a new Indiana University study. The researchers identified numerous obstacles, including a paucity of inter-agency influence and a failure to establish streamlined systems of care.
A study of four European trials found that HPV-based screening provided greater protection against invasive cervical cancer than cytological screening. The analysis showed that HPV-based screening protected 60-70% more women from invasive cancers, with increased protection seen in women aged 30-35 years and those screened every 5 years.
The study found that HPV vaccine initiation and completion rates were consistently lowest in the South, with 14% and 6% of women completing the series, respectively. The researchers believe regional disparities may be due to factors such as income, education, and insurance coverage.
A study by University of Manchester scientists found that less than 7% of cervical cancer patients in Kenya receive optimal treatment, leading to high mortality rates. The researchers are now seeking funding to implement simple changes in hospital procedures to improve cancer treatment in the country.
Researchers at Duke University Medical Center found that HPV subtypes affecting African-American women differ significantly from those covered by available vaccines. This disparity raises concerns about the vaccines' effectiveness in preventing cervical cancer among African-American women.
Many parents believe the HPV vaccine is unnecessary or unsafe, which poses a barrier to its success. Experts argue that clinicians must engage with parents and address their concerns through open conversations and science-based information. Social media may also play a role in future HPV vaccination programs.
A special issue of Preventive Medicine explores common misconceptions about the HPV vaccine, including concerns about sexual disinhibition and vaccine safety. Studies show that these fears are largely unfounded, and that the vaccine can help prevent cervical cancer and other HPV-associated cancers.
A new study explores why low-income parents, particularly those from minority groups, may not be getting the human papillomavirus (HPV) vaccine. English-speaking parents expressed concerns about the vaccine's need and safety, while Spanish-speaking parents feared the vaccine would encourage sexual activity due to lack of provider expla...
A study published at IDWeek 2013 found that low-income girls from Spanish-speaking families were less likely to receive the HPV vaccine due to a lack of encouragement from healthcare providers, while English-speaking parents cited concerns over vaccine safety and perceived risk. The findings highlight the importance of culturally sensi...
A randomized controlled trial of 147 women with stage IIIB cervical cancer found that adding cisplatin to radiation therapy and high-dose-rate brachytherapy improved disease-free survival and reduced late toxicity, while maintaining acceptable acute toxicity levels.
A study by Brigham and Women's Hospital found that brachytherapy was associated with better cause-specific survival and overall survival in women with cervical cancer. The treatment's decline in the US may be related to increased adoption of alternative techniques.
Researchers found African-American women are 18.2% less likely to get vaccinated compared to white counterparts, despite access to healthcare. The study suggests health providers should bolster recommendations and address negative attitudes toward the vaccine.
Researchers have discovered significant genomic differences between adenocarcinoma and squamous cell carcinoma types of cervical cancer. High rates of PIK3CA mutations were found in both subtypes, while KRAS mutations were only present in adenocarcinomas. These findings suggest that targeted therapies may improve patient outcomes.
Cervical cancer is a significant burden on women of reproductive age in low- and middle-income countries, with reduced reproductive capacity and associated health risks. Experts argue that cervical cancer screening and treatment should be included in the post-2015 development agenda for improving reproductive health outcomes.
Research by UNSW academics links human papillomavirus (HPV) to an increased risk of esophageal squamous cell carcinoma, a type of oesophageal cancer. HPV is one of several factors contributing to the development of OSCC, which is more prevalent in certain countries like China, South Africa, and Iran.
A new study suggests that STD clinics can provide essential access to cervical cancer screenings for underscreened women. The majority of women participating in the study were eager to receive the screening, and most reported not having had a pap smear in at least three years.
Researchers found that 'virus-negative' genital warts can harbor small amounts of more distantly related viruses that escaped previous detection. The study identified 23 new types of HPV and two known sequences, highlighting the diverse pool of previously unknown HPV types infecting humans.
Less than one third of obstetrician-gynecologists vaccinate patients against HPV, while only half follow cervical cancer prevention guidelines. Physician-patient interactions are a major barrier to guideline implementation.
A recent study found that many obstetrician-gynecologists continue to provide annual cervical-cancer screenings despite updated guidelines. The research suggests less frequent screening every three years can retain most benefits while reducing harms and costs. Experts recommend a more balanced approach to cervical cancer screening.
Researchers identify specific genes linked to cervical cancer's development and warn against using antiviral therapies in some cases. The findings may improve diagnosis of potentially dangerous lesions, but highlight the need for caution when using these treatments.
Researchers found that medical specialists can identify abnormality in breast and cervical cancer images with high accuracy, outperforming random guessing. However, localizing the issue proves challenging even for experts.
Doctors at WashU Medicine have shown that testing cervical tumors before treatment can predict whether patients will do well with standard chemotherapy. The study supports personalized medicine for cervical cancer, a tumor normally treated with a one-size-fits-all approach.
A BUSM study found that low-income and minority parents are more receptive to HPV vaccination, while white, middle-class parents defer vaccination. Vaccination can reduce health disparities in cervical cancer rates if girls are vaccinated before sexual experimentation.
A new study suggests that young women are more likely to get vaccinated against HPV if the emphasis is on preventing sexually transmitted diseases rather than cancer. The study found that messages focusing on genital warts were more effective in encouraging college-aged women to discuss vaccination with their doctors.
A study found that training women to self-collect genital samples for HPV testing can increase cervical cancer screening coverage in Kenya. Self-collection showed strong agreement with physician-collected samples, indicating its potential as a viable means to detect cervical lesions.
A recent study found that immune responses to HPV-16 and HPV-18 infection were noninferior in girls receiving two doses of the HPV vaccine compared to those receiving three doses. The study suggests a possible reduced-dose schedule for HPV vaccination, which could improve vaccine uptake rates and reduce costs.
Recent studies have shown that image-guided brachytherapy can deliver high doses of radiotherapy to tumours while sparing surrounding organs, leading to effective treatment with fewer side-effects. The studies also found a clear dose response relationship between radiation dose and vaginal morbidity.
Researchers found high numbers of HPV type 53 in normal cervical smears from HIV positive women, but not in cervical cancers. This sub-type may inhibit progression to cervical cancer, potentially providing a simple biological therapy for prevention.